Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Onyee Chan

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Blood Cancer Journal|November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeRami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative NeoplasmsFranco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Blood Advances|July 30, 2020
Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplantSeongseok Yun, Onyee Chan, Daniel Kerr, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid LeukemiaAkriti G Jain, Somedeb Ball, Luis E Aguirre, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 27, 2022
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid LeukemiaDasom Lee, Akriti G Jain, Yehuda Deutsch, et al.
Blood Advances|April 14, 2023
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromesRami S Komrokji, Luis E Aguirre, Najla H Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2020
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase KaryotypeZaker I Schwabkey, Najla Al Ali, Onyee Chan, et al.
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Annals of Hematology|November 29, 2023
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbiditiesNathan P Horvat, Enas F Abdallah, Zhuoer Xie, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Blood Cancer Journal|November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeRami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative NeoplasmsFranco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Blood Advances|July 30, 2020
Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplantSeongseok Yun, Onyee Chan, Daniel Kerr, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid LeukemiaAkriti G Jain, Somedeb Ball, Luis E Aguirre, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 27, 2022
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid LeukemiaDasom Lee, Akriti G Jain, Yehuda Deutsch, et al.
Blood Advances|April 14, 2023
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromesRami S Komrokji, Luis E Aguirre, Najla H Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2020
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase KaryotypeZaker I Schwabkey, Najla Al Ali, Onyee Chan, et al.
Cancer|August 9, 2022
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlatesAndrew T Kuykendall, Qianxing Mo, David A Sallman, et al.
Annals of Hematology|November 29, 2023
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbiditiesNathan P Horvat, Enas F Abdallah, Zhuoer Xie, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Pageof 8